Edmond de Rothschild Holding’s Acadia Pharmaceuticals ACAD Stock Holding History

Edmond de Rothschild Holding’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-154,160	Closed	-$8.24M	–	724
2020 Q4	$8.24M	Hold	154,160	–	–	0.28%	104
2020 Q3	$6.36M	Buy	154,160 +33,500	+28%	+$1.45M	0.25%	104
2020 Q2	$5.85M	Hold	120,660	–	–	0.24%	116
2020 Q1	$5.1M	Buy	120,660 +48,560	+67%	+$2M	0.27%	107
2019 Q4	$3.08M	Sell	72,100 -33,900	-32%	-$1.47M	0.12%	146
2019 Q3	$3.81M	Sell	106,000 -194,300	-65%	-$5.89M	0.15%	131
2019 Q2	$8.03M	Sell	300,300 -81,700	-21%	-$2.09M	0.3%	84
2019 Q1	$10.3M	Sell	382,000 -30,000	-7%	-$701K	0.35%	74
2018 Q4	$6.66M	Buy	412,000 +2,000	+0.5%	+$38.8K	0.23%	92
2018 Q3	$8.51M	Buy	410,000 +40,548	+11%	+$638K	0.24%	90
2018 Q2	$5.64M	Buy	369,452 +29,452	+9%	+$525K	0.16%	124
2018 Q1	$7.64M	Hold	340,000	–	–	0.22%	104
2017 Q4	$10.2M	Sell	340,000 -125,000	-27%	-$4M	0.29%	88
2017 Q3	$17.5M	Sell	465,000 -10,000	-2%	-$325K	0.5%	63
2017 Q2	$13.2M	Buy	475,000 +158,620	+50%	+$4.73M	0.37%	72
2017 Q1	$10.9M	Buy	316,380 +216,380	+216%	+$7.64M	0.29%	83
2016 Q4	$2.88M	Buy	+100,000	New	+$2.65M	0.08%	168

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

FAM

Fred Alger Management New York $30B AUM 76.99% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Edmond de Rothschild Holding's ACAD Position: Q1 2021 in Review

Edmond de Rothschild Holding sold out of Acadia Pharmaceuticals (ACAD) in Q1 2021, closing a stake of 154,160 shares — an estimated $8.24M sold.

Edmond de Rothschild Holding first reported a position in ACAD in Q4 2016 and held it in 17 quarters. The position peaked at $17.5M in Q3 2017. 272 funds tracked by Wall St. Rank hold ACAD as of Q1 2021.

Edmond de Rothschild Holding reported no remaining Acadia Pharmaceuticals position as of Q1 2021 after selling out during the quarter.
Edmond de Rothschild Holding sold 154,160 Acadia Pharmaceuticals shares in Q1 2021, an estimated $8.24M.
Edmond de Rothschild Holding first reported a position in Acadia Pharmaceuticals in Q4 2016 and held it in 17 quarters.
Edmond de Rothschild Holding's Acadia Pharmaceuticals position peaked at $17.5M in Q3 2017.
272 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2021.

Based on Edmond de Rothschild Holding's 13F filing for Q1 2021, filed 17 May 2021.